Compare Quest Diagnostics Inc (DGX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Visa Inc — how do they compare? Quest Diagnostics Inc trades at $230.17 (market cap $25.48B), while Visa Inc trades at $380.4 (market cap $704.20B). The key difference: Visa Inc is far larger — about 27.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Visa Inc for 115 Days on average.
| DGX | V | |
|---|---|---|
Market Cap | $25.48B | $704.20B |
Volume | 941,866 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $247.45 | $384.14 |
52-Week Low | $173.49 | $295.52 |
Typical Hold Time | 56 Days | 115 Days |
Enterprise Value | $31.23B | $714.78B |
Dividend Yield | 1.49% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Visa (V) trades at $372.10, up 0.39% with strong bullish technical momentum. The company demonstrates robust fundamentals with 2025 revenue of $40B and net income margin of 50.78%. Recent earnings beats and a consensus price target of $422.24 reflect Wall Street optimism. Visa's expansion into AI-powered commerce through Intelligent Commerce Connect positions it for future growth while maintaining exceptional profitability metrics including 61.79% ROE.
Visa presents a compelling investment case with consistent earnings outperformance and dominant market position. Key opportunities include AI integration and stablecoin partnerships, while risks involve regulatory scrutiny and fintech competition. With 85% analyst buy ratings and 13% upside to consensus target, the stock offers growth potential despite premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
